Post by Bell Potter Securities

Bell Potter is delighted to have acted as Joint Lead Manager and Bookrunner to Vitrafy Life Sciences (ASX:VFY) $30.0 million Placement. Vitrafy is a technology company which has successfully developed an innovative cryopreservation platform. The outcomes from this technology have delivered outstanding results, most recently demonstrated by the trials completed by the US Army Institute of Surgical Research on frozen blood platelets.  The Placement was conducted after Vitrafy announced its first major collaboration in the US civilian human blood sector with Vitalant – the 2nd largest blood collection network in the US – seeking to address the global critical need for a new Red Blood Cell solution. The transaction received strong support from existing shareholders and new institutional investors, with net proceeds to be used to fund the manufacturing of its Guardion devices to meet anticipated strong demand.   Matthew Baxter, Director of Corporate Finance, comments: “Congratulations to the entire Vitrafy team on their successful equity raising. Vitrafy is very well positioned to capture the structural tailwind created by the 2027 phase-out of legacy red blood cell technologies and accelerating demand for higher-quality biological preservation solutions. The Placement is a significant validation of the opportunity available for Vitrafy” Congratulations to Brent Owens, Simon Martin and Tim Sharpe from Vitrafy Life Sciences, as well as the Bell Potter team including Matthew Baxter, Matthew Zema and Callum Wishart. Disclosure: Bell Potter Securities acted as Joint Lead Manager and Bookrunner to the $30m ASX Capital Raise for Vitrafy Life Sciences and received fees for that service.